The Uromigos

GU Oncology Now

During the second-annual Uromigos Live &amp; Unplugged event, Thomas Powles, MBBS, MRCP, MD, chaired a livestreamed RCC session that included lively discussion from Mike Atkins, MD; David McDermott, MD; and Brian Rini, MD.Together, they weigh the results of the RENOTORCH study findings presented at ESMO and whether those data influenced their opinions on first-line IO treatment for metastatic disease. They also consider the results of CheckMate 214, KEYNOTE-426, CheckMate 9ER, and CLEAR.View the <a href="https://guoncologynow.com/post/uromigos-live-2023-management-of-io-refractory-rcc" target="_blank" rel="noopener">first kidney cancer session</a> of the day on management of IO-refractory disease.

Uromigos Live 2023: Frontline Metastatic Renal Cancer: Time for Reflection

Uromigos Live 2023

Dr. Powles chaired a livestreamed RCC session that included lively discussion from Drs. Atkins, McDermott, and Rini.

Frontline Metastatic Renal Cancer: Time for Reflection

About Us

Contributors and Partners

Editorial Policy

Advertising

eNewsletters

Calendar

Contact Us

Contribute

MashupMD

Cancer Nursing Today

Urban Health Today

Blood Cancers Today

DocWire News

Knowledge Hubs

Conference Coverage

Roundtables

Uromigos Live 2024

AUC3

Localized

mHSPC/mCSPC

CRPC

Diagnostics

Prostate Cancer

Localized Renal Cell Carcinoma

Advanced Renal Cell Carcinoma

nccRCC

Renal Cell Carcinoma

Non-Muscle Invasive Urothelial Carcinoma

Muscle Invasive Urothelial Carcinoma

Advanced Urothelial Carcinoma

Upper Tract Urothelial Carcinoma

Urothelial Carcinoma

Testicular, Penile, and Rare Cancers

Video Insights

Advancements in Oncology

The Oncology Brothers

Expert Interviews

Journal

Subscribe